Danisei Group is building a full-cycle international healthcare ecosystem. Below is a summary of our financial trajectory, growth roadmap and key documents for current and prospective investors.
Nine complementary divisions create cross-selling synergies and a defensible moat across the healthcare value chain.
Digital biology and AI drug discovery position the group at the technology frontier of pharmaceutical innovation.
A modeled, milestone-based revenue ramp from pilot launch to full regional scale by 2029.